Sarcopenia in ElderlyFrailty/SarcopeniaOncological PatientsHematologic Disease
Investigational drug(s) / intervention(s)
Frailty evaluation
Frailty evaluation: Evaluation of the frailty impact on the toxicity grade 3-4 in patients undergoing chemotherapy treatment.
Study summary
The Italian population is progressively aging, and cancer incidence increases with age. Older patients are at higher risk of frailty, a condition associated with adverse outcomes such as disability, falls, hospitalization, and mortality.
Key indicators of frailty include reduced balance, impaired physical activity, cognitive decline, and particularly sarcopenia, defined as the progressive loss of skeletal muscle mass and strength. After age 60, muscle mass decreases by 1.4-2.5% annually, while muscle strength declines by 15% between ages 60-70 and by up to 30% per decade thereafter.
Sarcopenia increases the risk of falls, fractures, hospitalization, and non-cancer-related death. In cancer patients, its prevalence ranges from 11% to 74% and is associated with poorer survival outcomes in both early and advanced disease stages.In clinical oncology practice, several tools are available to assess frailty, identify vulnerable patients, and personalize care, treatment, and supportive interventions.
Eligibility
Sex
ALL
Min age
70 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Inclusion criteria for patients with solid tumors:
* Cytological or histological diagnosis of lung cancer or gastrointestinal tract tumors (esophageal, gastric, intestinal, colorectal, pancreatic, and biliary tract cancers), mesothelioma.
* Age ≥ 70 years
* Patients deemed eligible, at the investigator's discretion, for first-line treatment including at least one chemotherapeutic agent
* Previous treatments (e.g., adjuvant therapy) are allowed if completed at least one year prior to randomization
* ECOG performance status 0, 1, or 2
* Written informed consent obtained
Inclusion criteria for patients with hematologic malignancies:
* Cytological or histological diagnosis of multiple myeloma or lymphoma
* Age ≥ 70 years
* Patients deemed eligible, at the investigator's discretion, for first-line systemic treatment
* ECOG performance status 0, 1, 2, or 3
* Written informed consent obtained
Exclusion Criteria:
* Brain metastases (in solid tumors)
* Symptomatic bone lesions (in solid tumors)
* Cardiac disease classified as NYHA class III or IV
* Current or prior prostate or breast cancer receiving hormonal therapy (GnRH agonists or antagonists, androgen inhibitors, estrogen inhibitors)
* Acute leukemia
* Patients with pacemakers or implantable cardioverter-defibrillators (ICD)
Primary outcome measure(s)
Impact of frailty on grade 3-4 Chemotherapy Toxicity in Patients with Solid and Hematologic Malignancies. — 12 months from screening Evaluation of the impact of frailty on the probability of grade 3 or 4 toxicity in patients with solid or hematologic malignancies undergoing chemotherapy treatment.
Multidimensional geriatric assessment including:
G8 (0-17): ≤14 = frail/vulnerable; \>14 = normal. IADL (0-8): higher scores indicate greater independence. CCI: 0-2 = low comorbidity; ≥3 = high comorbidity burden. SPPB (0-12): 10-12 = good, 7-9 = intermediate, ≤6 = poor physical performance. MUST: 0 = low, 1 = medium, ≥2 = high risk of malnutrition. Mini-Cog (0-5): ≥3 = normal cognition; \<3 = cognitive impairment. CARG: low, intermediate, or high risk of severe chemotherapy toxicity. MNA: ≥24 = normal; 17-23.5 = at risk of malnutrition; \<17 = malnourished. Laboratory tests: routine pre-chemotherapy assessments according to institutional standards.
BIA: evaluation of body composition, muscle mass, and phase angle. CT/MRI: assessment of muscle area at L3/L4; sarcopenia defined as \<4.8 cm²/m² in women and \<6.6 cm²/m² in men
Trial sites (1)
Facility
City
Region
Status
Trial Office-ASST Ovest Milanese
Legnano
Italy
More Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
